Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4)

被引:21
|
作者
Mumaw, Michele M. [1 ]
de la Fuente, Maria [1 ]
Arachiche, Amal [1 ]
Wahl, James K., III [2 ]
Nieman, Marvin T. [1 ]
机构
[1] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[2] Univ Nebraska Med Ctr, Coll Dent, Dept Oral Biol, Lincoln, NE USA
基金
美国国家卫生研究院;
关键词
Protease activated receptor 4; Monoclonal antibody; G-protein coupled receptor; Thrombin receptor; Platelets; HUMAN PLATELET-AGGREGATION; THROMBIN RECEPTOR; ALPHA-THROMBIN; SIGNALING AXIS; CLEAVAGE; MECHANISM; SITE; RACE; INFLAMMATION; STIMULATION;
D O I
10.1016/j.thromres.2015.03.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Protease activated receptor 4 (PAR4) is a G protein coupled receptor (GPCR) which is activated by proteolytic cleavage of its N-terminal exodomain. This generates a tethered ligand that activates the receptor and triggers downstream signaling events. With the current focus in the development of anti-platelet therapies shifted towards PARs, new reagents are needed for expanding the field's knowledge on PAR4. Currently, there are no PAR4 reagents which are able to detect activation of the receptor. Methods: Monoclonal PAR4 antibodies were purified from hybridomas producing antibody that were generated by fusing splenocytes with NS-1 cells. Immunoblotting, immunofluorescence, and flow cytometry were utilized to detect the epitope for each antibody and to evaluate the interaction of the antibodies with cells. Results: Here, we report the successful generation of three monoclonal antibodies to the N-terminal extracellular domain of PAR4: 14H6, 5 F10, and 2D6. We mapped the epitope on PAR4 of 14H6, 5 F10, and 2D6 antibodies to residues (48-53), (41-47), and (73-78), respectively. Two of the antibodies (14H6 and 5 F10) interacted close to the thrombin cleavage and were sensitive to alpha-thrombin cleavage of PAR4. In addition, 5 F10 was able to partially inhibit the cleavage of PAR4 expressed in HEK293 cells by alpha-thrombin. Conclusions: These new antibodies provide a means to monitor endogenous PAR4 expression and activation by proteases on cells. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1165 / 1171
页数:7
相关论文
共 50 条
  • [21] Protease-Activated Receptor-4 (PAR4) Inhibits Pro-Nociceptive Signals and Visceral Hypersensitivity
    Auge, Celine
    Cenac, Nicolas
    Balz-Hara, Daniela
    Vergnolle, Nathalie
    GASTROENTEROLOGY, 2009, 136 (05) : A722 - A722
  • [22] Expression and Purification of Protease-Activated Receptor 4 (PAR4) and Analysis with Histidine Hydrogen-Deuterium Exchange
    de la Fuente, Maria
    Han, Xu
    Miyagi, Masaru
    Nieman, Marvin T.
    BIOCHEMISTRY, 2020, 59 (05) : 671 - 681
  • [23] Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
    Wong, Pancras C.
    Seiffert, Dietmar
    Bird, J. Eileen
    Watson, Carol A.
    Bostwick, Jeffrey S.
    Giancarli, Mary
    Allegretto, Nick
    Hua, Ji
    Harden, David
    Guay, Jocelyne
    Callejo, Mario
    Miller, Michael M.
    Lawrence, R. Michael
    Banville, Jacques
    Guy, Julia
    Maxwell, Brad D.
    Priestley, E. Scott
    Marinier, Anne
    Wexler, Ruth R.
    Bouvier, Michel
    Gordon, David A.
    Schumacher, William A.
    Yang, Jing
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (371)
  • [24] Molecular cloning of the rat proteinase-activated receptor 4 (PAR4)
    Hoogerwerf, WA
    Hellmich, HL
    Micci, MA
    Winston, JH
    Zou, L
    Pasricha, PJ
    BMC MOLECULAR BIOLOGY, 2002, 3
  • [25] A Hypo-reactive Protease Activated Receptor 4 (PAR4) Variant is Associated With a Reduced Risk of Venous Thromboembolism
    Han, Xu
    Knauss, Elizabeth
    Nayak, Lalitha
    Nieman, Marvin T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2020, 40
  • [26] Protease-activated receptors: PAR4 and counting: how long is the course?
    Hollenberg, MD
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (07) : 271 - 273
  • [27] Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog
    Lin, Yu-Chuan
    Ko, Yen-Chun
    Hung, Shang-Cheng
    Lin, Ying-Ting
    Lee, Jia-Hau
    Tsai, Ju-Ying
    Kung, Po-Hsiung
    Tsai, Meng-Chun
    Chen, Yih-Fung
    Wu, Chin-Chung
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 694 - 703
  • [28] Elevated protease-activated receptor 4 (PAR4) gene expression in Alzheimer's disease predicts cognitive decline
    Winfree, Rebecca L.
    Erreger, Kevin
    Phillips, Jared
    Seto, Mabel
    Wang, Yanling
    Schneider, Julie A.
    Bennett, David A.
    Schrag, Matthew S.
    Hohman, Timothy J.
    Hamm, Heidi E.
    NEUROBIOLOGY OF AGING, 2024, 140 : 93 - 101
  • [29] Complement factor C4a does not activate protease-activated receptor 1 (PAR1) or PAR4 on human platelets
    Han, Xu
    de la Fuente, Maria
    Nieman, Marvin T.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (01) : 104 - 110
  • [30] Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions
    Bilodeau, Matthew L.
    Hamm, Heidi E.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (02): : 778 - 788